Sec Form 13D Filing - Griffin Highline Capital LLC filing for KINGSTONE COMPANIES, INC (KINS) - 2022-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

KINGSTONE COMPANIES, INC.

(Name of Issuer)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

496719105

(CUSIP Number)

Michael Doak

c/o Griffin Highline Capital LLC

4514 Cole Avenue, Suite 1650

Dallas, Texas 75205

(917) 508-5887

with a copy to:

Sean M. Ewen, Esq.

Willkie Farr & Gallagher, LLP

787 Seventh Avenue

New York, New York 10019

(212) 728-8000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 2, 2022

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 59560V109

CUSIP No. 59560V109

Item 1. Security and Issuer

This statement on Schedule 13D (this “Schedule 13D”) relates to Common Stock, $0.01 par value per share (the “Common Stock”), of Kingstone Companies, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is located at 15 Joys Lane, Kingston, NY 12401.

The initial Schedule 13D filed on February 11, 2021, as amended by Amendment No. 1 filed on January 18, 2022, and as amended by Amendment No. 2 filed on May 4, 2022, is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 3.

Item 4. Purpose of Transaction

Item 4 is hereby supplemented as follows:

As previously reported, on May 4, 2022, GHC submitted a preliminary non-binding indication of interest to the Board of Directors of the Issuer proposing a transaction whereby an entity formed by GHC would acquire all of the outstanding equity of the Issuer, after taking into account the “rollover” of the shares held by the Reporting Persons. Since that time, GHC has conducted due diligence regarding and in collaboration with the Company subject to the Confidentiality Agreement previously filed as Exhibit 99.3 to this Schedule 13D. On August 2, 2022, following substantial completion of its due diligence and after discussions with the Company, GHC submitted a final non-binding indication of interest to the Board of Directors of the Issuer proposing a transaction whereby an entity formed by GHC would acquire all of the outstanding equity of the Issuer, after taking into account the “rollover” of the shares held by the Reporting Persons, on the terms, conditions and assumptions described therein. The purchase price for the proposed transaction would be funded with fully committed equity and assumes the refinancing of the issuer’s third party debt on agreed upon terms. Following delivery of the non-binding proposal, the issuer agreed to extend the period of exclusivity with GHC under its previously executed exclusivity agreement for a limited time period to further pursue the proposal. No assurances can be given that a transaction will be consummated and the parties reserve the right to withdraw the proposal at any time. The transaction may result in one or more of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, including, without limitation, the acquisition of additional securities of the Issuer, a merger or other extraordinary transaction involving the Issuer, the delisting of Common Stock from the Nasdaq Stock Market and the Common Stock becoming eligible for termination of registration pursuant to Section 12(g) of the Act.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 4, 2022